 |
PDBsum entry 3mec
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Crystal structures of HIV-1 reverse transcriptase with etravirine (tmc125) and rilpivirine (tmc278): implications for drug design.
|
 |
|
Authors
|
 |
E.B.Lansdon,
K.M.Brendza,
M.Hung,
R.Wang,
S.Mukund,
D.Jin,
G.Birkus,
N.Kutty,
X.Liu.
|
 |
|
Ref.
|
 |
J Med Chem, 2010,
53,
4295-4299.
|
 |
|
PubMed id
|
 |
|
 |
|
|
 |
 |
|
Abstract
|
 |
|
Diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitors (NNRTIs)
have inherent flexibility, helping to maintain activity against a wide range of
resistance mutations. Crystal structures were determined with wild-type and
K103N HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine
(TMC278). These structures reveal a similar binding mode for TMC125 and TMC278,
whether bound to wild-type or K103N RT. Comparison to previously published
structures reveals differences in binding modes for TMC125 and differences in
protein conformation for TMC278.
|
 |
|
|
|
|
 |